ADIL Adial Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ADIL

Price (delayed)

$1.93

Market cap

$7.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.6

Enterprise value

$5M

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, ...

Highlights
Adial Pharmaceuticals's quick ratio has surged by 94% YoY
ADIL's equity has soared by 75% QoQ and by 25% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.adialpharma.com
Peers: NWBO

Key stats

What are the main financial stats of ADIL
Market
Shares outstanding
4.05M
Market cap
$7.83M
Enterprise value
$5M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.58
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$5.12M
EBITDA
-$5.12M
Free cash flow
-$6.81M
Per share
EPS
-$3.6
Free cash flow per share
-$4.78
Book value per share
$3.35
Revenue per share
$0
TBVPS
$3.32
Balance sheet
Total assets
$4.74M
Total liabilities
$653,076
Debt
$0
Equity
$4.08M
Working capital
$2.55M
Liquidity
Debt to equity
0
Current ratio
4.9
Quick ratio
4.33
Net debt/EBITDA
0.55
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-134.1%
Return on equity
-183.3%
Return on invested capital
-402%
Return on capital employed
-125.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADIL stock price

How has the Adial Pharmaceuticals stock price performed over time
Intraday
-11.06%
1 week
-17.17%
1 month
16.97%
1 year
-74.25%
YTD
3.76%
QTD
45.11%

Financial performance

How have Adial Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$6.89M
Net income
-$5.12M
Gross margin
N/A
Net margin
N/A
Adial Pharmaceuticals's net income has soared by 60% YoY and by 16% from the previous quarter
The operating income rose by 37% year-on-year and by 18% since the previous quarter

Growth

What is Adial Pharmaceuticals's growth rate over time

Valuation

What is Adial Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 72% YoY and by 37% QoQ
The stock's price to book (P/B) is 88% less than its 5-year quarterly average of 4.7 and 79% less than its last 4 quarters average of 2.7
ADIL's equity has soared by 75% QoQ and by 25% YoY

Efficiency

How efficient is Adial Pharmaceuticals business performance
The ROIC rose by 37% QoQ
ADIL's ROE is up by 22% QoQ
ADIL's return on assets is up by 10% since the previous quarter

Dividends

What is ADIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADIL.

Financial health

How did Adial Pharmaceuticals financials performed over time
ADIL's current ratio has surged by 128% since the previous quarter and by 84% year-on-year
Adial Pharmaceuticals's quick ratio has surged by 94% YoY
Adial Pharmaceuticals's debt is 100% less than its equity
ADIL's equity has soared by 75% QoQ and by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.